Immune subtyping for pancreatic cancer with implication in clinical outcomes and improving immunotherapy

被引:0
作者
Jingkai Liu
Qiaofei Liu
Xiang Zhang
Ming Cui
Tong Li
Yalu Zhang
Quan Liao
机构
[1] Chinese Academy of Medical Sciences,Department of General Surgery, Peking Union Medical College Hospital, Peking Union Medical College
来源
Cancer Cell International | / 21卷
关键词
Pancreatic cancer; Heterogeneity; Immune cell; Immune checkpoints; Immunotherapy; Transglutaminase 2;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 337 条
[1]  
Siegel RL(2019)Cancer statistics, 2019 CA A Cancer J Clin 69 7-34
[2]  
Miller KD(2018)Therapeutic developments in pancreatic cancer: current and future perspectives Nat Rev Gastroenterol Hepatol 15 333-348
[3]  
Jemal A(2018)Cancer immunotherapy using checkpoint blockade Science 359 1350-1355
[4]  
Neoptolemos JP(2018)Emerging role of immune checkpoint blockade in pancreatic cancer Int J Mol Sci 19 3505-584
[5]  
Kleeff J(2015)Combination cancer immunotherapy and new immunomodulatory targets Nat Rev Drug Discov 14 561-220
[6]  
Michl P(2019)Molecular subtypes of pancreatic cancer Nat Rev Gastroenterol Hepatol 16 207-830.e814
[7]  
Costello E(2018)The immune landscape of cancer Immunity 48 812-539
[8]  
Greenhalf W(2002)Transglutaminase 2: an enigmatic enzyme with diverse functions Trends Biochem Sci 27 534-8795
[9]  
Palmer DH(2006)Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-κB in cancer cells: delineation of a novel pathway Can Res 66 8788-2005
[10]  
Antoni R(2008)Tissue transglutaminase regulates focal adhesion kinase/AKT activation by modulating PTEN expression in pancreatic cancer cells Clin Cancer Res 14 1997-958